Monopar Therapeutics - 8-K Filing

Monopar Therapeutics reports Q3 2026 net loss of $6.2 million and expects cash runway through March 31, 2028. (Items: 2.02 Results of Operations and Financial Condition On November 12, 2026, Monopar Therapeutics Inc, 9.01 Financial Statements and Exhibits Exhibit No)

SEC EDGAR · November 12, 2026, 13:01 UTC

Tickers: $MNPR

Read the full article at SEC EDGAR

More Regulatory news

FILANA THERAPEUTICS, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 13:18 UTC
RUM Group Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:17 UTC
Theriva Biologics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:15 UTC
SeaStar Medical Holding Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 13:15 UTC
Avalyn Pharma Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:15 UTC
SES AI Corp - 8-K Filing SEC EDGAR · November 12, 2026, 13:15 UTC
Data443 Risk Mitigation, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:15 UTC
TRUSTMARK CORP - 8-K Filing SEC EDGAR · November 12, 2026, 13:15 UTC
SUBURBAN PROPANE PARTNERS LP - 8-K Filing SEC EDGAR · November 12, 2026, 13:14 UTC
MeiraGTx Holdings plc - 10-Q Filing SEC EDGAR · November 12, 2026, 13:13 UTC